Changeflow GovPing Pharma & Drug Safety Acellular Amniotic Fluid for Ischemic Injury Tr...
Routine Notice Added Final

Acellular Amniotic Fluid for Ischemic Injury Treatment

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

USPTO granted patent US12599635B2 to University of Utah Research Foundation covering compositions and methods for treating ischemic injuries using acellular amniotic fluid (acAF). The patent names inventors Hadi Javan, Craig H. Selzman, Young Sook Lee, Jo-Anna Reems, and Jan L. Pierce, and includes 31 claims. The patent application was filed March 22, 2021 under application number 17912730.

What changed

USPTO granted patent US12599635B2 to University of Utah Research Foundation for compositions and methods of treating ischemic injuries using acellular amniotic fluid. The patent covers administering therapeutically effective amounts of acAF to ischemic injury sites within therapeutic time windows. Healthcare providers and researchers should monitor this intellectual property development as it may affect future research directions and potential licensing opportunities for ischemic injury treatments.

For pharmaceutical companies and medical researchers, this patent establishes exclusive rights for the use of acellular amniotic fluid in ischemic injury treatment, potentially limiting independent development of similar therapies without licensing arrangements with the assignee.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Compositions and treatments for ischemic injuries

Grant US12599635B2 Kind: B2 Apr 14, 2026

Assignee

University of Utah Research Foundation

Inventors

Hadi Javan, Craig H. Selzman, Young Sook Lee, Jo-Anna Reems, Jan L. Pierce

Abstract

Described herein are compositions and methods for treating ischemic injury in a subject comprising administering a therapeutically effective amount of an acellular amniotic fluid (acAF) to an ischemic injury situs within a therapeutic time window.

CPC Classifications

A61K 35/50 A61K 38/014 A61K 31/728 A61K 2300/00 A61P 9/10

Filing Date

2021-03-22

Application No.

17912730

Claims

31

View original document →

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12599635B2

Who this affects

Applies to
Healthcare providers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent licensing Medical treatment Therapeutic development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!